Despite the evidence on the growing number of antipsychotic users and the potential increased risk of diabetes and hyperprolactinemia in the pediatric population, the incidence proportion of those who received monitoring for glucose and prolactin before and after drug initiation is remarkably low. This evidence concerns the gene PRL and hyperprolactinemia.